🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. OXALIPLATIN, CALCIUM FOLINATE, FLUOROURACIL, BNT327 20 mg ml, CAPECITABINE, BEVACIZUMAB, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, BNT327 50 mg ml, CAPECITABINE

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  2. OXALIPLATIN, CALCIUM LEVOFOLINATE, FOLINIC ACID, FLUOROURACIL

    Ningbo Cancer Hospital

    Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery

    phase 3 small molecule active

    1 trial

  3. OXALIPLATIN, FOLINIC ACID, IRINOTECAN, FLUOROURACIL

    Ningbo Cancer Hospital

    High-risk stage III colon cancer

    phase 3 small molecule active

    1 trial

  4. Obatoclax Mesylate, Carboplatine and Etoposide

    Teva Pharma GmbH

    Extensive-stage Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  5. Olaparib

    AstraZeneca

    Breast Cancer Metastatic

    phase 3 small molecule completed

    1 trial

  6. Olaparib 300mg tablets

    AstraZeneca

    Relapsed Ovarian Cancer

    phase 3 small molecule completed

    1 trial

  7. Olaparib, CISPLATIN , Olaparib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED , CARBOPLATIN

    Merck Sharp and Dohme

    Stage IV lung cancer condition

    phase 3 small molecule active

    1 trial

  8. Olaparib, ETOPOSIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pembrolizumab placebo (saline), Olaparib matching placebo (tablet), CARBOPLATIN , CISPLATIN , Olaparib

    Merck Sharp and Dohme

    Participants with Limited Stage-Small Cell Lung Cancer, who have received no prior anticancer therapy for their disease.

    phase 3 small molecule active

    1 trial

  9. Opevesostat, FLUDROCORTISONE, PREDNISOLONE, DEXAMETHASONE ACETATE, HYDROCORTISONE, FLUDROCORTISONE ACETATE, ABIRATERONE ACETATE, DEXAMETHASONE, ABIRATERONE ACETATE, HYDROCORTISONE, HYDROCORTISONE, ENZALUTAMIDE, HYDROCORTISONE, PREDNISONE, PREDNISONE ACETATE, HYDROCORTISONE

    Merck Sharp and Dohme

    Metastatic castration resistant prostate cancer

    phase 3 small molecule active

    1 trial

  10. Oral immunonutrition

    Hospital Authority, Hong Kong

    Non Small Cell Lung Cancer

    phase 3 other active

    1 trial

  11. Orteronel

    Takeda

    Prostate Cancer

    phase 3 small molecule completed

    3 trials

  12. Osimertinib

    AstraZeneca

    Cancer

    phase 3 small molecule active

    1 trial

  13. Oxaliplatin

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 3 small molecule active

    1 trial

  14. PACLITAXEL , BNT327, PEMETREXED , CARBOPLATIN , BNT327, PEMBROLIZUMAB

    BioNTech SE

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  15. PACLITAXEL , GEMCITABINE , CARBOPLATIN , BNT327, Abraxane 5 mg/ml powder for dispersion for infusion., ERIBULIN , BNT327 Placebo

    BioNTech SE

    First line triple-negative breast cancer (TNBC)

    phase 3 small molecule active

    1 trial

  16. PACLITAXEL , Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, GEMCITABINE, FOLINIC ACID, FLUOROURACIL

    CERO THERAPEUTICS HOLDINGS, INC.

    Metastatic pancreatic cancer

    phase 3 small molecule active

    1 trial

  17. PACLITAXEL , Trodelvy 200 mg powder for concentrate for solution for infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion

    Gilead Sciences Pty Limited

    Recurrent or Persistent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  18. PACLITAXEL, ALPELISIB, DOXORUBICIN HYDROCHLORIDE, OLAPARIB, ALPELISIB, OLAPARIB

    Novartis Pharmaceuticals

    Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation

    phase 3 small molecule active

    1 trial

  19. PACLITAXEL, CARBOPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, Placebo to MK-7339 100 mg, Placebo to MK-7339 150 mg, Olaparib, PACLITAXEL ALBUMIN-BOUND

    Merck Sharp and Dohme

    Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  20. PACLITAXEL, CISPLATIN, CARBOPLATIN, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMBROLIZUMAB, PEMETREXED, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PEMETREXED

    CERO THERAPEUTICS HOLDINGS, INC.

    Non small cell lung cancer

    phase 3 small molecule active

    1 trial

  21. PACLITAXEL, FLUOROURACIL, DOCETAXEL, EXEMESTANE, DOXORUBICIN, CYCLOPHOSPHAMIDE, EPIRUBICIN, LETROZOLE, TAMOXIFEN, ANASTROZOLE

    Ningbo Cancer Hospital

    patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®

    phase 3 small molecule active

    1 trial

  22. PACLITAXEL, GEMCITABINE HYDROCHLORIDE, MYCOPHENOLATE MOFETIL, GEMCITABINE, CISPLATIN, INFLIXIMAB, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, IMFINZI 50 mg/mL concentrate for solution for infusion.

    AstraZeneca AB

    Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB; either squamous or non-squamous).

    phase 3 small molecule active

    1 trial

  23. PACLITAXEL, LEUPRORELIN, GOSERELIN, TRIPTORELIN, EPIRUBICIN, TRIPTORELIN, EXEMESTANE, RIBOCICLIB, CYCLOPHOSPHAMIDE, LETROZOLE, DOXORUBICIN, GOSERELIN, LEUPRORELIN, ANASTROZOLE, PACLITAXEL ALBUMIN-BOUND, DOCETAXEL

    Ningbo Cancer Hospital

    Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  24. PACLITAXEL, MYCOPHENOLATE MOFETIL, Abraxane 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion., Rilvegostomig, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CARBOPLATIN, INFLIXIMAB

    AstraZeneca AB

    Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources